Novel vanilloid receptor-1 antagonists: 3. The identification of a second-generation clinical candidate with improved physicochemical and pharmacokinetic properties

Journal of Medicinal Chemistry

Volumn 50, Issue 15, 2007, Pages 3528-3539

  Wang, Hui Ling ^a   Katon, Jodie ^b   Balan, Chenera ^a   Bannon, Anthony W ^a   Bernard, Charles ^a   Doherty, Elizabeth M ^a   Dominguez, Celia ^a   Gavva, Narender R ^a   Gore, Vijay ^a   Ma, Vu ^a   Nishimura, Nobuko ^a   Surapaneni, Sekhar ^a   Tang, Phi ^a   Tamir, Rami ^a   Thiel, Oliver ^a   Treanor, James J S ^a   Norman, Mark H ^a  

^a AMGEN INC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMG 517; ANALGESIC AGENT; N [4 [6 [4 [1 (4 FLUOROPHENYL)ETHYL]PIPERAZIN 1 YL]PYRIMIDIN 4 YLOXY]BENZO[D]THIAZOL 2 YL]ACETAMIDE; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1; VANILLOID RECEPTOR 1 ANTAGONIST;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AQUEOUS SOLUTION; ARTICLE; CONTROLLED STUDY; DOG; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; HYPERALGESIA; IC 50; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PHYSICAL CHEMISTRY; RAT; THERMODYNAMICS;

ANALGESICS; ANIMALS; BENZOTHIAZOLES; CHO CELLS; CRICETINAE; CRICETULUS; DOGS; DRUG STABILITY; HAPLORHINI; HUMANS; HYPERALGESIA; MALE; PAIN MEASUREMENT; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; THERMODYNAMICS; TRPV CATION CHANNELS;

EID: 34547556499     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm070191h     Document Type: Article

References (24)

1. (a) Caterina, M. J.; Schumacher, M. A.; Tominaga, M.; Rosen, T. A.; Levine, J. D.; Julius, D. The Capsaicin Receptor: A Heat-Activated Ion Channel in the Pain Pathway. Nature 1997, 389, 816-824.
2. (b) Montell, C.; Birnbaumer, L.; Flockerzi, V.; Bindels, R. J.; Bruford, E. A.; Caterina, M. J.; Clapham, D. E.; Harteneck, C.; Heler, S.; Julius, D.; Kojima, I.; Mori, Y.; Penner, R.; Prawitt D.; Scharenberg, A. M.; Schultz, G.; Shimizu, N.; Zhu, M. X. A Unified Nomenclature for the Superfamily of TRP Cation Channels. Mol. Cell 2002, 9, 229-231.
3. (c) Clapham, D. TRP Channels as Cellular Sensors. Nature 2003, 426, 517-524.
4. (d) Szallasi, A.; Blumberg, P. M. Vanilloid (Capsaicin) Receptors and Mechanisms. Pharmacol. Rev. 1999, 51, 159-212.
5. For reviews see: (a) Appendino, G.; Munoz, E.; Fiebich, B. L. TRPV1 (Vanilloid Receptor, Capsaicin Receptor) Agonists and Antagonists. Expert Opin. Ther. Pat. 2003, 13 (12), 1825-1837
6. (b) Szallasi, A.; Appendino, G. Vanilloid Receptor TRPV1 Antagonists as the Next Generation of Painkillers. J. Med. Chem. 2004, 47 (11), 1-7.
7. (c) Roberts, L.; Connor, M. TRPV1 Antagonists as a Potential Treatment for Hyperalgesia. Recent Pat. CNS Drug Discovery 2006, 1, 65-76.
8. (d) Geppetii, P.; Materazzi, S.; Nicoletti, P. The Transient Receptor Potential Vanilloid 1: Role in Airway Inflammation and Disease. Eur. J. Pharmacol. 2006, 533, 207-214 and references therein.
9. Doherty, E. M.; Fotsch, C.; Bo, Y.; Chakrabarti, P.; Chen, N.; Gavva, N.; Han, N.; Kelly, M. G.; Kincaid, J.; Klionsky, L.; J.; Liu Q.; Ognyanov, V. I.; Tamir, R.; Wang, Q.; Zhu, Z.; Norman, M. H.; Treanor, J. J. S. Discovery of Potent, Orally Available Vanilloid Receptor-1 Antagonists. Structure-Activity Relationship of N-Aryl Cinnamides. J. Med. Chem. 2005, 48, 71-90.
10. Xi, N.; Bo, Y.; Doherty, E. M.; Fotsch, C.; Gavva N.; Han, N.; Hungate, R. W.; Klionsky, L.; Liu, Q.; Tamir, R.; Xu, S.; Treanor, J. J. S.; Norman, M. H. Synthesis and Evaluation of Thiazole Carboxamides as Vanilloid Receptor 1 (TRPV1) Antagonists. Bioorg. Med. Chem. Lett. 2005, 15, 5211-5217.
11. Ognyanov, V. I.; Balan, C.; Bannon, A. W.; Bo, Y.; Dominguez, C.; Fotsch, C.; Gore, V. K.; Klionsky, L.; Ma, V. M.; Qian Y.-X.; Tamir, R.; Wang, X.; Xi, N.; Xu, S.; Zhu, D.; Gavva, N. R.; Treanor, J. J. S.; Norman, M. H. Design of Potent, Orally Available Antagonists of Transient Receptor Potential Vanilloid 1 Structure-Activity Relationships of 2-(Piperazin-1-yl)-1H- benzimidazoles. J. Med. Chem. 2006, 49 (12), 3719-3742
12. Norman, M. H.; Fotsch, C.; Doherty, E. M.; Bo, Y.; Chen, N.; Chakrabarti, P.; Gavva, N. R.; Nishimura, N.; Nixey, T.; Ognyanov, V. I.; Rzasa, R.; Stec, M.; Surapaneni, S.; Tamir, R.; Viswanadhan, V.; Zhu, J.; Treanor, J. J. S. Novel Vanilloid Receptor-1 Antagonists: 1. Conformationally Restricted Analogues of trans-Cinnamides. J. Med. Chem. 2007, 50, 3497-3514.
13. Doherty, E. M.; Bannon, A. W.; Bo, Y.; Chen, N.; Dominguez, C.; Falsey, J. Fotsch, C.; Gavva, N. R.; Katon, J.; Nixey, T.; Ognyanov, V. I.; Pettus, L.; Rzasa, R.; Stec, M.; Surapaneni, S.; Tamir, R.; Zhu, J.; Treanor, J. J. S.; Norman, M. H. Novel Vanilloid Receptor-1 Antagonists: 2. Structure-Activity Relationships of 4-Oxopyrimidines Leading to the Selection of a Clinical Candidate. J. Med. Chem. 2007, 50, 3515-3527.
14. Tan, H.; Semin, D.; Wacker, M.; Cheetham, J. An Automated Screening Assay for Determination of Aqueous Equilibrium Solubility Enabling SPR Study During Drug Lead Optimization. JALA 2005, 10 (6), 364-373.
15. Goodman, A. J.; Stanforth, S. P.; Tarbitb, B. Desymmetrization of Dichloroazaheterocycles. Tetrahedron 1999, 55, 15067-15070.
16. Eastwood, P. R. A Versatile Synthesis of 4-Aryl Tetrahydropyridines via Palladium-Mediated Suzuki Cross-Coupling with Cyclic Vinyl Boronates. Tetrahedron Lett. 2000, 41, 3705-3708.
17. 1H NMR spectrum.
18. (a) Opalka, C. J.; D'Ambra, T. E.; Facoone, J. J.; Bodson, G.; Cossement, E. A Novel Synthesis of the Enantiomers of an Antihistamine Drug by Piperazine Formation from a Primary Amine. Synthesis 1995, 766.
19. (b) Pflum, Derek, A.; Krishnamurthy, D.; Zhengxu, H.; Senanayke, S. A. Asymmetric Synthesis of Cetirizine Dihydrochloride. Tetrahedron Lett. 2002, 43, 923-926.
20. (c) Bazzicalupi, C.; Bencini, A.; Fusi, V.; Micheloni, M.; Paoletti, P.; Valtancoli, B. Synthetic Route to Produce Giant-Size Azamacrocycles. J. Org. Chem. 1994, 59, 7508-7510.
21. 50 values of compound 16p were greater than 4 mM at blocking TRP channels (hTRPV3, mTRPV1, rTRPM8, hTRPA1) that are structurally related to TRPV1.
22. (a) Wang, H.-L.; Balan, C.; Doherty, E. M.; Falsey, J. R.; Gore, V. K.; Katon, J.; Norman, M. H. Preparation of 4-heteroaryloxy-6-piperazinopyrimidines as vanilloid receptor ligands. US 2005/ 0176726 A1, 2005.
23. (b) Balan, C.; Chen, N.; Doherty, E. M.; Gore, V; K.; Norman, M. H.; Wang, H.-L. Preparation of 4-heteroaryloxy-6-piperazinopyrimidines and 2-heteroaryloxy-4-piperazinopyridines as vanilloid receptor ligands. US 2005/0182067 A1, 2005.
24. Poindexter, G. S.; Bruce, M. A.; Leboullec, K. L.; Monokovic, I. Use of 2-Oxazolidinones as Latent Aziridine Equivalents. III. Preparation of N-Substituted Piperazines. Tetrahedron Lett. 1994, 35, 7331-7334.